Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Cash & Equivalents	139.39	151.02	149.16	152.11	29.25	22.19
Cash & Cash Equivalents	139.39	151.02	149.16	152.11	29.25	22.19
Cash Growth	-9.18%	1.25%	-1.94%	420.04%	31.84%	-3.47%
Other Current Assets	5.13	3.36	3.55	9.51	5.29	3.14
Total Current Assets	144.52	154.39	152.71	161.62	34.54	25.33
Total Assets	144.52	154.39	152.71	161.62	34.54	25.33
Accounts Payable	3.73	4.32	3.83	4.74	3.99	3.52
Deferred Revenue	0.92	0.92	0.44	0.44	0	0
Other Current Liabilities	4.92	7.3	5.95	5.61	3.32	1.52
Total Current Liabilities	9.56	12.53	10.21	10.8	7.31	5.04
Total Liabilities	9.56	12.53	10.21	10.8	7.31	5.04
Retained Earnings	-312.24	-293.07	-245.56	-197.59	-159.68	-133.4
Shareholders' Equity	134.96	141.85	142.49	150.82	27.24	20.29
Net Cash / Debt	139.39	151.02	149.16	152.11	29.25	22.19
Net Cash / Debt Growth	-9.18%	1.25%	-1.94%	420.04%	31.84%	-3.47%
Net Cash Per Share	1.69	1.89	1.94	2.18	0.50	0.45
Working Capital	134.96	141.85	142.49	150.82	27.24	20.29
Book Value Per Share	1.64	1.78	1.85	2.16	0.47	0.41

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).